BAX and hepatocellular carcinoma: On the other hand, combinational treatment of HCC with azilsartan – an ARB – and Bay11-7082 – an NFκB antagonist – was found to induce apoptosis pathways by elevating ROS, thus releasing cytochrome c from the mitochondria into the cytosol and reducing the Bcl-2/Bax ratio in HCC (25).